Based on Ultragenyx Pharmaceutical, Inc.’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $24.15 million and GAAP net loss of $99.17 million. In comparison, last year the company earned revenue of $12.79 million and had a GAAP net loss of $52.73 million. The company has a one-year high of $90.98 and a one-year low of $37.44. Currently, Ultragenyx Pharmaceutical, Inc. has an average volume of 533.14K.
Starting in February 2019, RARE received 22 Buy ratings in a row. Eight different firms, including Barclays and Cowen & Co., currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.